Healthcare
Live Price
Offline$0.4785
+0.00% today
1Y Change
-7.13%
Window
Jun 20, 2025 → Jun 15, 2026
Coverage: 253 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Senzime AB (publ) (SNZZF) is a Healthcare stock with a market cap of $740.00M and listed on OTC. The stock last traded around $0.48 and down 7.1% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +77.4%, EPS growth of +3.2%, a dividend yield of 0.0%. What stands out right now is revenue +77.4%, EPS +3.2%, free cash flow +11.7% with operating margin -116.3% and ROIC -36.8%. Valuation sits in the middle of the pack at price/sales 7.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SNZZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNZZF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNZZF Max Drawdown
-38.85%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNZZF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$11.0M
-21.8% YoY
FY Net Income
-$82.1M
+38.1% YoY
Free Cash Flow
-$84.3M
+40.6% YoY
Revenue Growth
+77.4%
EPS Growth
+3.2%
Gross Margin
31.0%
Net Margin
-120.7%
Income statement
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 104M | 58M | 36M | 14M | 11M |
| Gross Profit | 31M | 20M | 8M | -4M | -5M |
| Operating Income | -121M | -124M | -137M | -134M | -84M |
| EBITDA | -96M | -96M | -116M | -120M | -73M |
| Net Income | -137M | -119M | -134M | -133M | -82M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 74M | 101M | 151M | 26M | 75M |
| Total Assets | 369M | 425M | 434M | 323M | 175M |
| Total Liabilities | 65M | 79M | 58M | 61M | 24M |
| Shareholder Equity | 304M | 346M | 375M | 262M | 151M |
| Total Debt | 26M | 23M | 11M | 13M | 2M |
| Net Debt | -47M | -78M | -140M | -13M | -73M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
81M
+40.5% YoY
Capital Expenditures
3M
+41.8% YoY
Free Cash Flow
84M
+40.6% YoY
Key ratios
Gross Margin
31.0%
Operating Margin
-116.3%
Net Margin
-120.7%
ROE
-38.3%
Debt / Equity
0.08x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.